Table 2.

The information of aPL data in COVID-19 patients from different cohorts.

Male/Female	Age range	positive rate of aPL and its subtypes	Patients type
10/9	36–80	aPL: 52.6%; LA: 5.3%; aCL: IgA 31.6%; IgG 10.5%; IgM:5.3% aβ2GPI: IgA 36.8%; IgG 31.6%	Critically ill COVID-19 [7]
Total: 56	Not provided	aPL: 48.2%; LA: 45%; aCL or aβ2GPI: 10%	COVID-19 patients [8]
24/11	19–83	LA: 91%	COVID-19 patients with a prolonged aPTT (≥30s) [9]
97/75	25–95	aPL:52%; aPS/PT: IgG: 24%; IgM 18%; aCL: IgG 4.7%; IgM 23%; IgA 3.5% aβ2GPI: IgG 2.9%; IgM 5.2%; IgA 4.1%	COVID-19 patients [10]
60/62	Age (mean ± SD): 54.3 ± 19.3	aPL: 43.4%; LA: 22.2%; aCL: IgG 13.4%; IgM 2.7%; IgA 1.7% aβ2GPI: IgG 6.3%; IgM 7.1%; IgA 3.3%	53 hospitalised and 69 home-quarantined patients [11]
9/12	54–67	aPL: 57.1%; aPS: IgG 0; IgM 0; aCL: IgG 9.5%; IgM 14.3% aβ2GPI: IgG 4.8%; IgM 0; aPT: IgG 0; IgM 14.3%	severe or critical COVID-19 [12]
34/34	LA negative 50.45 ± 20.19; LA positive: 64.77 ± 13.84	LA: 44.1%; aCL: IgG 0; IgM 1.6% aβ2GPI: IgG 0; IgM 1.7%	COVID-19 patients [13]
21/8	43–85	aPL: 55.2%; aCL: IgG 24.1%; IgM 10.3%; aβ2GPI: IgG 17.2%; IgM 27.6%	severely ill covid-19 patients [5]
17/16	22–90	aPL: 24.2%; aCL: IgG 9.1%; IgM 15.2%; aβ2GPI: IgG 6.1%; IgM 6.1%	consecutive COVID-19 patients [6]